A model combining BI-RADS® descriptors from pre-treatment B-mode breast ultrasound with clinicopathological tumor features shows promise in the prediction of residual disease after neoadjuvant chemotherapy
-
Published:2024-09
Issue:
Volume:178
Page:111649
-
ISSN:0720-048X
-
Container-title:European Journal of Radiology
-
language:en
-
Short-container-title:European Journal of Radiology
Author:
Kapetas PanagiotisORCID,
Aggarwal Reena,
Altuwayjiri Basmah,
Pinker Katja,
Clauser Paola,
Helbich Thomas H.,
Baltzer Pascal A.T.
Reference51 articles.
1. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline;Korde;J. Clin. Oncol.,2021
2. M. Asaoka, S. Gandhi, T. Ishikawa, K. Takabe, Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future, Breast Cancer (Auckl) 14 (2020) 1178223420980377. Doi: 10.1177/1178223420980377.
3. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox;Dubsky;Lancet Oncol.,2021
4. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer;Wang;Drug Des. Devel. Ther.,2020
5. RECIST for response (clinical and imaging) in neoadjuvant clinical trials in operable breast cancer;Semiglazov;J. Natl. Cancer Inst. Monogr.,2015